Wei-Lei Yang PhD, Barbara A. Crothers DO, Tien-Jen Liu MD, Shih-Wen Hsu MS, Cheng-Hung Yeh MS, Yi-Siou Liu MS, Guowei Shao MS, Ming-Yu Lin PhD, Tang-Yi Tsao MD, Min-Che Tung MD, Pei-Yi Chu MD, Jen-Fan Hang MD, FIAC
{"title":"Does artificial intelligence redefine nuclear-to-cytoplasmic ratio threshold for diagnosing high-grade urothelial carcinoma?","authors":"Wei-Lei Yang PhD, Barbara A. Crothers DO, Tien-Jen Liu MD, Shih-Wen Hsu MS, Cheng-Hung Yeh MS, Yi-Siou Liu MS, Guowei Shao MS, Ming-Yu Lin PhD, Tang-Yi Tsao MD, Min-Che Tung MD, Pei-Yi Chu MD, Jen-Fan Hang MD, FIAC","doi":"10.1002/cncy.70017","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The Paris System (TPS) introduced standardized nuclear-to-cytoplasmic (N/C) ratio thresholds for urine cytology to improve high-grade urothelial carcinoma (HGUC) detection, but these criteria remain subjective. This study used AIxURO, an artificial intelligence-based model, to measure N/C ratio and nuclear area to identify abnormal cells in whole slide images (WSIs).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 106 urine cytology slides from 46 lower urinary tract (LUT) and 60 upper urinary tract (UUT) cancer cases, diagnosed as atypical urothelial cell (15.1%), suspicious for high-grade urothelial carcinoma (SHGUC) (23.6%), and HGUC (61.3%), with biopsy-confirmed HGUC or carcinoma in situ (CIS), were digitized and analyzed by AIxURO. The model quantified suspicious and atypical cells, N/C ratios, and nuclear areas, with statistical differences assessed using Kruskal–Wallis tests.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>AIxURO identified fewer suspicious cells than atypical cells (20.5 vs. 242.0, <i>p</i> < .001). Suspicious cells had higher N/C ratios (0.66 vs. 0.58, <i>p</i> < .001) and larger nuclear areas (102.3 vs. 85.7 µm<sup>2</sup>, <i>p</i> < .001). Although N/C ratios did not differ significantly between UUT and LUT cases, nuclear areas varied among abnormal cells (CIS: 101.5 µm<sup>2</sup>; HGUC: 83.5 µm<sup>2</sup>). In HGUC cytology cases, the CIS category had larger nuclear areas than HGUC for both suspicious (116.3 vs. 100.4 µm<sup>2</sup>) and atypical cells (101.5 vs. 82.2 µm<sup>2</sup>).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>AIxURO provides objective quantification of N/C ratios and nuclear areas, refining TPS criteria for distinguishing suspicious from atypical cells. A lower N/C ratio cutoff (0.66) for SHGUC/HGUC may be more appropriate than the TPS threshold (>0.7). Findings support using consistent N/C ratio criteria across UUT and LUT cases.</p>\n </section>\n </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"133 5","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.70017","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cytopathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncy.70017","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The Paris System (TPS) introduced standardized nuclear-to-cytoplasmic (N/C) ratio thresholds for urine cytology to improve high-grade urothelial carcinoma (HGUC) detection, but these criteria remain subjective. This study used AIxURO, an artificial intelligence-based model, to measure N/C ratio and nuclear area to identify abnormal cells in whole slide images (WSIs).
Methods
A total of 106 urine cytology slides from 46 lower urinary tract (LUT) and 60 upper urinary tract (UUT) cancer cases, diagnosed as atypical urothelial cell (15.1%), suspicious for high-grade urothelial carcinoma (SHGUC) (23.6%), and HGUC (61.3%), with biopsy-confirmed HGUC or carcinoma in situ (CIS), were digitized and analyzed by AIxURO. The model quantified suspicious and atypical cells, N/C ratios, and nuclear areas, with statistical differences assessed using Kruskal–Wallis tests.
Results
AIxURO identified fewer suspicious cells than atypical cells (20.5 vs. 242.0, p < .001). Suspicious cells had higher N/C ratios (0.66 vs. 0.58, p < .001) and larger nuclear areas (102.3 vs. 85.7 µm2, p < .001). Although N/C ratios did not differ significantly between UUT and LUT cases, nuclear areas varied among abnormal cells (CIS: 101.5 µm2; HGUC: 83.5 µm2). In HGUC cytology cases, the CIS category had larger nuclear areas than HGUC for both suspicious (116.3 vs. 100.4 µm2) and atypical cells (101.5 vs. 82.2 µm2).
Conclusions
AIxURO provides objective quantification of N/C ratios and nuclear areas, refining TPS criteria for distinguishing suspicious from atypical cells. A lower N/C ratio cutoff (0.66) for SHGUC/HGUC may be more appropriate than the TPS threshold (>0.7). Findings support using consistent N/C ratio criteria across UUT and LUT cases.
巴黎系统(TPS)引入了标准化的尿细胞学核/细胞质(N/C)比值阈值,以提高高级别尿路上皮癌(HGUC)的检测,但这些标准仍然是主观的。本研究采用基于人工智能的AIxURO模型,测量N/C比率和核面积,以识别全片图像(WSIs)中的异常细胞。方法对诊断为非典型尿路上皮细胞(15.1%)、怀疑为高级别尿路上皮癌(SHGUC)(23.6%)、怀疑为HGUC(61.3%)、活检证实为HGUC或原位癌(CIS)的46例下尿路癌(LUT)和60例上尿路癌(UUT)患者的106张尿细胞学切片进行数字化分析。该模型量化了可疑和非典型细胞、N/C比率和核面积,并使用Kruskal-Wallis试验评估了统计差异。结果AIxURO鉴定出的可疑细胞少于非典型细胞(20.5 vs. 242.0, p <;措施)。可疑细胞的N/C比值较高(0.66 vs. 0.58, p <;.001)和更大的核区域(102.3 vs. 85.7µm2, p <;措施)。尽管在UUT和LUT病例中N/C比率没有显著差异,但异常细胞的核面积存在差异(CIS: 101.5µm2;HGUC: 83.5µm2)。在HGUC细胞学病例中,CIS类别的可疑细胞(116.3 vs 100.4µm2)和非典型细胞(101.5 vs 82.2µm2)的核面积都比HGUC大。结论AIxURO提供了客观定量的N/C比和核面积,完善了TPS标准,用于区分可疑细胞和非典型细胞。SHGUC/HGUC较低的N/C比值临界值(0.66)可能比TPS阈值(>0.7)更合适。研究结果支持在UUT和LUT病例中使用一致的N/C比率标准。
期刊介绍:
Cancer Cytopathology provides a unique forum for interaction and dissemination of original research and educational information relevant to the practice of cytopathology and its related oncologic disciplines. The journal strives to have a positive effect on cancer prevention, early detection, diagnosis, and cure by the publication of high-quality content. The mission of Cancer Cytopathology is to present and inform readers of new applications, technological advances, cutting-edge research, novel applications of molecular techniques, and relevant review articles related to cytopathology.